Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

20%

3 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

4 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

5(38.5%)

Phase 3

3(23.1%)

Phase 1

3(23.1%)

Early Phase 1

2(15.4%)

13Total

Phase 2(5)

Phase 3(3)

Phase 1(3)

Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT04895631Phase 3Completed

18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

Role: lead

NCT07052760Early Phase 1Withdrawn

Imaging of Solid Tumors Using DLL3 SPECT

Role: lead

NCT06961084Phase 2Recruiting

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Role: lead

NCT07054346Phase 1Recruiting

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Role: lead

NCT04044937Phase 2Completed

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

Role: lead

NCT04621435Phase 1Recruiting

Imaging of Solid Tumors Using FAP-2286

Role: lead

NCT07218224Unknown

Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas

Role: lead

NCT05180162Phase 1Completed

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

Role: lead

NCT06474533Recruiting

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Role: lead

NCT04716725Phase 2Active Not Recruiting

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT03353740Phase 3Completed

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

Role: lead

NCT03764007Phase 2Completed

18F-Fluorocholine for the Detection of Parathyroid Adenomas

Role: lead

NCT03803475Phase 3Completed

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

Role: lead

NCT02611882Phase 2Completed

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

Role: lead

NCT03197012Early Phase 1Completed

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Role: lead

All 15 trials loaded